The immune intervention based on these antibodies may lay a foundation for future diagnosis and treatment for liver cancers that are positive for MAN2A1-FER gene fusion since these antibodies can be humanized to form diagnostic imaging reagents such as flourine18-labeled antibodies specific for MAN2A1-FER–positive cancers and to form therapeutic reagents such as drug-conjugated/radio-labeled antibodies, chimera antigen receptor T cells, or cancer cell targeting delivery vehicles in the cancer treatment. Here, MAN2A1 is linked to liver cancer.